Top 17 Paychecks in Big Pharma
by Tracy Staton and Maureen Martino
Few statistics are as hotly debated as CEO pay reports. Investors, analysts, and the just plain curious all want to know how much the head honcho makes--and how one company's chief stacks up against another's. So here for your rubbernecking pleasure are the 17 highest-paid CEOs in Big Pharma. While the names themselves probably won't be a surprise, their pecking order might. For instance, the biggest drugmaker by sales--Pfizer--doesn't have the highest-paid executive, and one of the relatively small fry counts its chief among the top 10.
We've already ranked CEO pay at the industry's top five biotechs, but it's worth noting that if they had been included on this list, Amgen's Kevin Sharer and Genentech's Arthur Levinson would have ranked fifth and sixth behind Wyeth's Bob Essner. Genzyme's Henri Termeer made $14.6 million in 2007, coming in ahead of Merck's Richard Clark, and Gilead's John Martin made $10.8 million, slightly less than Roche's Humer.
For U.S. companies, FiercePharma's numbers are based on total compensation reported in their proxy statements. The numbers include base salary, bonus and "other" compensation in 2007. For overseas companies not required to file proxies in the U.S., we gleaned executive pay information from various press reports. Though we did as much due diligence as we could to make sure these reported totals were apples-to-apples comparisons, there's a chance we may have missed something. Feel free to let us know.
1. Miles White - Abbott - $33.4M
2. Fred Hassan - Schering-Plough - $30.1M
3. Bill Weldon - Johnson & Johnson - $25.1M
4. Bob Essner - Wyeth - $24.1M
5. Robert Parkinson - Baxter - $17.6M
6. Daniel Vasella - Novartis - $15.5M
7. Richard Clark - Merck - $14.5M
8. Frank Baldino - Cephalon - $13.5M
9. Sidney Taurel - Eli Lilly - $13M
10. Jeff Kindler - Pfizer - $12.6M
11. Jim Cornelius - Bristol-Myers Squibb - $11.3
12. Franz Humer - Roche - $11.1M
13. Robert Coury - Mylan - $8.5M
14. Jean-Pierre Garnier - GlaxoSmithKline - $6M
15. Werner Wenning - Bayer - $4.77M
16. David Brennan - AstraZeneca - $4.3M
17. Gerard Le Fur - Sanofi-Aventis - $3.27M
Comments
Interesting how the European companies CEO compensation is much lower than the US CEOs. This despite the fact that Roche, Novartis and SanofiAventis are among the largest companies. Bottom line: US CEOs are overcompensated both relative to the market and the size/productivity of their firms. Knowing this excessive pay filters quite far down the management tree, there is a heck of a lot of money being spent on overpaid, underperforming excecutives that could be returned to shareholders or ploughed right back into imactful R&D. (the difference between Miles White and David Brennan's compensation alonewould fund ~10+ Phase 1 trials, or one meaningful Phase3 registration study!)
The bottom line is that in a free market system the "invisible hand" does a fairly good overall job in allocating resources. Why don't people complain about Tiger Woods' 2008 $122 million compensation?
Because Tiger is being paid for performance. How many of these guys are? If he messed up as badly as Merck has, he wouldn't be getting anywhere near what he makes.
And Tiger doesn't have a golden parachute. If he were to do something unacceptable, he would be out on his ear.
Where have all the leaders gone? In a time when big pharma is leading the corporate pack in losses and reduced shareholder value executives continue to be exempt from accountability for the poor performance of their corporation. Instead of finding ways to increase revenues and and grow the bottom line they are getting fat payouts for cost cutting through layoffs and cost efficiencies.
This is a short term solution with long term consequences and is unsustainable. Anyone can cost cut anyone can lay off people anyone can find ways to cut expense. Leaders find creative solutions and are held accountable for their performance. I for one can drive a company into the ground for a lot less than what most of the CEO's are being payed. It about time shareholders hold CEO's accountable and tie their pay to performance much like the employees they have so thoughtfully laid off. Although that would take a decision by the board and well, that means they have to be tied to performance as well.
Couldn't agree more with the last poster!
With a record year of LAYOFFS and the additional 2,400 from Merck and Wyeth combined weeks ago brings the total to around 45,000 employees in 2007 from 10 pharm/biotech companies.
Do you realize the number of people looking for work in 2008 from these 10 companies is equivalent to the number of approximate casualties from the earthquake in China.
Those that haven't been affected directly by the slash of these overpaid corporate executives don't realize the tremendous silent impact this has had on a medium size suburb in the US.
When is someone going to take the helm and make some real impact on our healthcare industry? Politicians continue to say reform is overdue and point the finger at big pharma. These ego maniac CEO's need to realize that we have the largest population of US citizens that require their leadership. Stop taking the easy short road to shareholder profits. Have some courage and make the tough decision. There is no reason, what so ever, why this industry shouldn't be expanding to accomodate the boomers that are in need.
The grossly high pay is concentrated primarily in US CEOs. The pay for heads of GSK, Bayer, Sanofi and A-Z are all relatively lower. The data are consistent with prior observations of a US-EU differential on this point.
Tiger Woods? How about Lebron James at $90 million a year? Plus the team can't even get to the third round of the play offs.
Also remember, most US companies were taken from the Germans in the 1940's, their assets siezed from Hitler, thats why there is Merk, Merk AG, Shering Shering AG, and on and on. Biotech, the United States is light years ahead of Europe, so come up with those drugs for cancer, ms, etc., and you have earned your money in saving lives, hosptial and doctor care. Medicine is 9 cents of every healthcare dollar and has risen less than hospital or physician cost more than any other component, but many complain, for their insurance does not pay it all, they have to pay a copay more than the doctor. People doon't even look at their physician and hospitial bills after a stay. Then you will see why employers are going broke, they can not afford healthcare for the U.S. worker. Its not a CEO at a drug companies salary, pick another cause, for your facts are all screwed up here.
The reason some of these highly paid; poorly performing CEOs get kicked out after years of underperforming is that they usually stack the board of directors in their favor by removing hostile uncontrollable members and replace them with puppets who get paid to keep the CEO in office.
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends

